Key facts
- Bio App’s last known valuation is $87.3M (Jul 2022).
- It has raised $3.8M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Posco Investment, EcoPro Partners, BNK Venture Capital, CKD Venture Capital, DT & Investment — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Bio App
- ·The full record, as it builds
Funding rounds
No funding rounds for Bio App are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bio App
Operator of a biotechnology company intended to offer a plant-derived genetically modified subunit vaccine for the prevention of swine fever. The company researches and develops plant-based green vaccine products for swine fever and African swine fever, as well as human medicines such as COVID-19, enabling doctors to prescribe biomedicine without any fear of side effects.
- Sector
- Healthcare
- HQ
- Pohang, South Korea
- Founded
- 2011
- Employees
- 36
- Website
- bioapplications.global/
- Ownership
- Privately Held (backing)
Bio App doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bio App shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bio App in its N-PORT filings yet. We sweep new filings monthly.